CRA consultants analyzed market power and alleged anticompetitive conduct for a CNS therapy. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing. Also considered were effects on demand resulting from the change in the form of competition upon the launch of generic products.
Comments on the effect of algorithms and artificial intelligence on the likelihood of coordinated effects as described in Guideline 3 of the draft Merger Guidelines
In this note, we discuss how the Antitrust Division of the Department of Justice and the Federal Trade Commission (collectively, the Agencies) view the effect...